Telcare Collaborates With Onduo in Diabetes Management Program

Telcare, manufacturer of the world’s first U.S. Food and Drug Administration (FDA)-cleared cellular-enabled blood glucose monitor, has entered into a strategic collaboration with Onduo, a joint venture created by Verily (an Alphabet company) and Sanofi. Under this partnership, Telcare will serve as the supplier of remote blood glucose systems and the resulting data for patients enrolled in Onduo’s groundbreaking diabetes management program.
 
Onduo will leverage Telcare’s ability to deliver near real-time blood glucose results to create effective care management programs targeted primarily to the Type 2 diabetes community. The Onduo platform integrates service, hardware and software to provide access to personalized and convenient diabetes care. Onduo’s team of clinicians and experts combine proven medical practices with breakthrough technologies to help take the guess work out of diabetes.
 
“This is an incredibly exciting partnership for the Telcare team. I believe Onduo’s program will have a tremendous impact on the lives of the millions of people living with diabetes,” said Joseph H. Capper, president and CEO of BioTelemetry Inc., parent company of Telcare. “We are pleased to be able to support Onduo’s approach to diabetes and to be working with such a dedicated group of individuals.”
 
BioTelemetry Inc. is a wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care. The Telcare division, acquired by BioTelemetry in December 2016, is a digital-health company whose work includes development of the first FDA-cleared cellular-enabled glucometer and cloud-based diabetes data repository system. The Company’s focus is on providing a suite of offerings to support diabetes management, combining a connected glucometer, cloud-based analytics and care management tools that enhance care for people living with diabetes. 

Diabetes is a chronic disease characterized by elevated blood sugar due to inefficient or deficient insulin production. In 2014, it was estimated that 422 million people globally suffer from the disease.¹  Diabetes can be classified in two major subsets, type 1 and type 2. Type 1 diabetes is an autoimmune disease that occurs when the pancreas stops making insulin and therefore must be regulated via daily administration of insulin. Type 2 diabetes is a metabolic disorder in which a person’s body produces insulin, but is not able to regulate it efficiently.  Over time, the disease can result in serious or life threatening complications, including damage to the heart, eyes, kidneys and nerves.² It has been estimated that the global economic burden of diabetes is U.S. $827 billion.³
 
References
1. Roglic, G. (2016). Global report on diabetes. Retrieved August 08, 2016, from http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf?ua=1
2. National Diabetes Statistics Report, 2014. (2014). Retrieved August 8, 2016, from https://www.cdc.gov/diabetes/pdfs/library/diabetesreportcard2014.pdf
[3] NCD Risk Factor Collaboration (NCD-RisC). 3. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4*4 million participants. Lancet 2016; published online April 7. http://dx.doi.org/10.1016/S0140-6736(16)00618-8.